TB prevention study for children with and without HIV
Treatments studied
Part of Infections clinical trials.
This study tests a daily combination of two medicines, rifapentine and isoniazid (called 1HP), to prevent tuberculosis (TB) in children under 13 years old. It includes children who have been exposed to TB or are at high risk, both those living with HIV and those without HIV.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Child must be under 13 years old.
- Child must weigh between 6.6 pounds (3 kg) and 99 pounds (45 kg).
- Child must be at risk for TB, such as being in close contact with someone with active TB, or having a positive TB skin or blood test.
- If the child has HIV, they must be on stable HIV treatment for at least 12 weeks before starting the study.
- Child must not have active TB disease or have taken TB medicines recently.
- Parent or guardian must agree to the child's participation and follow study procedures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a shorter treatment for children with tuberculosis (TB) that is not drug-resistant. It aims to find out if a shorter regimen works as well as the standard longer one, making treatment easier for children and their families.
This study is testing whether a shorter course of TB medicine works just as well as the standard longer treatment for children with drug-susceptible tuberculosis. It aims to make treatment easier for families.
This trial tests a two-drug HIV treatment (dolutegravir and lamivudine) for people who also have active TB and are taking a standard TB medicine called rifampin. It is designed for those who have not yet started HIV treatment.
This trial tests if a short course of medication can prevent tuberculosis (TB) in children and teenagers who have been in close contact with someone who has active TB. The goal is to see if this approach can stop them from developing the disease.
This study tests personalized TB treatment schedules based on your individual risk factors. Researchers want to see if matching treatment intensity to your specific situation helps cure TB while minimizing side effects.
This Phase 2 study tests MTBVAC, a TB vaccine candidate, to see if it is safe and whether it helps the immune system. It may be a fit if you’re eligible for TB and HIV-related vaccine safety testing and can follow study visits and testing.
Hear when a new Tuberculosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.